The Medicines Company completed two pharmacodynamic trials evaluating the transition of its investigational acute intravenous antiplatelet agent, cangrelor, to chronic oral therapy with ticagrelor (Brilinta) or prasugrel (Effient) in patients with coronary artery disease. Three prior trials assessed the transition from cangrelor to oral clopidogrel in 25,000 CAD patients undergoing percutaneous intervention. These agents are administered with the goal of decreasing the risk of thrombotic events during and after percutaneous intervention.